| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab. |
| 掲載誌名 | 正式名：Liver international : official journal of the International Association for the Study of the Liver 略 称：Liver Int ISSNコード：14783231/14783223 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 45(10),pp.e70286 |
| 著者・共著者 | Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Toru Ishikawa, Kazuto Tajiri, Hideko Ohama, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Yuki Kanayama, Fujimasa Tada, Shinichiro Nakamura, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Hironori Tanaka, Hidenao Noritake, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, |
| 発行年月 | 2025/10 |
| 概要 | AIM/BACKGROUND:This study aimed to validate the CLEAR score, a simple prognostic tool for hepatocellular carcinoma (HCC) patients undergoing atezolizumab plus bevacizumab (Atez/Bev) therapy, based on serum lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels.MATERIALS/METHODS:From 2020 to 2023, 498 Japanese HCC patients receiving Atez/Bev therapy were enrolled. They were divided into a training set (n = 280; 13 designated cancer care hospitals) and a validation set (n = 218; 11 universities and their affiliated Japanese hospitals). In the training set, prognostic factors were analysed, leading to the development of the CLEAR score, which was then evaluated on the validation set.RESULTS:Baseline LDH beyond the upper normal limit (hazard ratio [HR] 1.97, 95% CI 1.48-2.64) and CRP (≥ 0.50 mg/dL) (HR 1.61, 95% CI 1.19-2.00) were identified as independent prognostic factors on multivariate analysis and used in the CLEAR score. In the training set, the median progression-free survival (PFS) times in patients with scores 0, 1 and 2 were 11.1 months, 9.1 months and 3.3 months, respectively (p < 0.001). The median overall survival (OS) times in patients with scores 0, 1 and 2 were not available, 15.3 months and 10.6 months, respectively (p < 0.001). Similar results were obtained in the validation set (median PFS and OS times for scores 0, 1 and 2 = 9.4, 6.9 and 4.3 and 30.6, 20.8 and 8.9 months, respectively, each p < 0.001).CONCLUSION:The CLEAR score provides a distinct and simple prediction of the prognosis of HCC patients receiving Atez/Bev therapy. |
| DOI | 10.1111/liv.70286 |
| PMID | 40970650 |